论文部分内容阅读
据统计,70％的肿瘤患者最终都需要进行放射治疗,但放疗由于肿瘤本身血运差乏氧等内在规律,而影响着放疗的疗效,寻找有效的放射增敏药剂成为有效和重要的一种手段。我们选用Z-A类衍生物对小鼠进行了较详细的放射增敏研究,以期找到一种对临床放疗有效的药物。 1.材料和方法 Z-A类药物系生化类制剂,由加拿大国立癌症研究院提供,白色粉末易容于水,化学性质稳定,分子量为214.1经我们测试:LD_(so)为:1486mg/kg,以无菌性注射用水配成500mg/ml的工作值,小鼠照射前50分钟行腹腔注射,注射剂量LD1/5用药后未发现小鼠有神经毒症状。
According to statistics, 70% of cancer patients eventually need to be treated with radiotherapy, but radiotherapy due to the inherent blood flow of the tumor itself poor oxygen and other internal rules, and affect the efficacy of radiotherapy, to find effective radiosensitizer has become an effective and important means. We used Z-A derivatives to conduct more detailed radiosensitization studies in mice in order to find a drug that is effective for clinical radiotherapy. 1. Materials and Methods ZA drugs are biochemical preparations provided by the Canadian National Cancer Institute. The white powder is easily soluble in water and has stable chemical properties. The molecular weight is 214.1. We tested: LD_(so) is: 1486 mg/kg. Sterile water for injection was given a working value of 500 mg/ml. The mice were injected intraperitoneally 50 minutes before the irradiation. No neurotoxic symptoms were found in the mice after the injection of LD1/5.